MedTrace Logo

Lymphocyte to Procalcitonin Ratio in Covid-19 Patients

NCT06620159 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 535

Last updated 2024-10-03

No results posted yet for this study

Summary

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.

Conditions

Sponsors & Collaborators

  • Suleyman Demirel University

    lead OTHER

Principal Investigators

  • Furkan Ç Oğuzlar, asst. prof. · suleyman demirel university faculty of medicine

Eligibility

Min Age
23 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2024-09-27
Completion
2024-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06620159 on ClinicalTrials.gov